LYON, FRANCE and CHESTER, NJ--(MARKET WIRE)--Jun 28, 2007 -- Molecular Biometrics (MB), a privately held metabolomics company, today announced that researchers will present results of three clinical studies investigating the use of ViaTest(TM)-E, the Company's non-invasive platform designed to assess embryo and gamete viability in IVF. ViaTest-E was developed using Molecular Biometrics' proprietary technology of biospectroscopy-based metabolomics (BSM(TM)). The results of these studies will be presented at The 23rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Lyon, France (July 1 - 4, 2007). Molecular Biometrics will also exhibit at ESHRE, where it will unveil and demonstrate the Company's proprietary BSM System prototype.
